Tissue-Specific Ablation of Prkar1a Causes Schwannomas by Suppressing Neurofibromatosis Protein Production  by Jones, Georgette N. et al.
Tissue-Specific Ablation of
Prkar1a Causes Schwannomas by
Suppressing Neurofibromatosis
Protein Production1,2
Georgette N. Jones*, Chhavy Tep†,
William H. Towns II*, Georgeta Mihai‡, Ian D. Tonks§,
Graham F. Kay§, Petra M. Schmalbrock‡,
Anat O. Stemmer-Rachamimov¶, Sung Ok Yoon†
and Lawrence S. Kirschner*,#
*Human Cancer Genetics Program, Department of
Molecular Virology, Immunology and Medical Genetics, The
Ohio State University, Columbus, OH 43210, USA; †Center
for Molecular Neurobiology, The Ohio State University,
Columbus, OH 43210, USA; ‡Department of Radiology,
The Ohio State University, Columbus, OH 43210, USA;
§Queensland Institute of Medical Research, Queensland,
Australia; ¶Department of Pathology, Massachusetts
General Hospital, Harvard University, Boston, MA, USA;
#Division of Endocrinology, Diabetes and Metabolism,
The Ohio State University, Columbus, OH 43210, USA
Abstract
Signaling events leading to Schwann cell tumor initiation have been extensively characterized in the context of
neurofibromatosis (NF). Similar tumors are also observed in patients with the endocrine neoplasia syndrome
Carney complex, which results from inactivating mutations in PRKAR1A. Loss of PRKAR1A causes enhanced pro-
tein kinase A activity, although the pathways leading to tumorigenesis are not well characterized. Tissue-specific
ablation of Prkar1a in neural crest precursor cells (TEC3KO mice) causes schwannomas with nearly 80% pene-
trance by 10 months. These heterogeneous neoplasms were clinically characterized as genetically engineered
mouse schwannomas, grades II and III. At the molecular level, analysis of the tumors revealed almost complete
loss of both NF proteins, despite the fact that transcript levels were increased, implying posttranscriptional regu-
lation. Although Erk and Akt signaling are typically enhanced in NF-associated tumors, we observed no activa-
tion of either of these pathways in TEC3KO tumors. Furthermore, the small G proteins Ras, Rac1, and RhoA
are all known to be involved with NF signaling. In TEC3KO tumors, all three molecules showed modest increases
in total protein, but only Rac1 showed significant activation. These data suggest that dysregulated protein ki-
nase A activation causes tumorigenesis through pathways that overlap but are distinct from those described in
NF tumorigenesis.
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Introduction
There are four human diseases associated with the formation of
Schwann cell tumors. These lesions are the hallmarks of the neuro-
fibromatosis (NF) syndromes, NF1 [von Recklinghausen disease, On-
line Mendelian Inheritance in Man (OMIM) #162200] and NF2
(OMIM #101000), as well as familial schwannomatosis (OMIM
#162091) and Carney complex (CNC, OMIM #160980). NF1 is
caused by mutations in the NF1 tumor suppressor (encoding neuro-
fibromin), and patients may clinically manifest Schwann cell neoplasia
as neurofibromas or as malignant peripheral nerve sheath tumors
Abbreviations: CNC, Carney complex; GAP, GTPase-activating protein; KO, knock
(ed) out; NF, neurofibromatosis; PKA, protein kinase A; PNST, peripheral nerve
sheath tumor; TEC, tyrosinase-enhanced Cre; TEC3KO, TEC3;Prkar1aloxP/loxP
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(MPNSTs). NF2 is also caused by mutations in a tumor suppressor
gene (NF2, which encodes the protein merlin). Patients with NF2
develop multiple benign schwannomas, including both the pathogno-
monic vestibular schwannomas as well as nonvestibular schwannomas.
Familial schwannomatosis, which has recently been suggested to be
caused by mutations in the SMARCB1 gene [1], seems only to involve
benign, nonvestibular schwannomas.
Schwannomas are also a component of CNC, an autosomal domi-
nant neoplasia syndrome characterized as the complex of spotty skin
pigmentation, myxomas, endocrine overactivity, and schwannomas
[2,3]. Schwannomas are observed in approximately 14% of CNC pa-
tients and have been designated histopathologically as psammomatous
melanotic schwannomas for their histopathologic appearance and
high degree of pigmentation. Because of their location in and around
the spinal column, these tumors are a significant cause of morbid-
ity and mortality for CNC patients [4]. At the genetic level, CNC
is caused by inactivating mutations in PRKAR1A, the gene that en-
codes the type 1A regulatory subunit for the cAMP-dependent pro-
tein kinase A (PKA), and patient tumors exhibit enhanced PKA
activity [5]. In a Prkar1a+/− mouse model, schwannomas were ob-
served in approximately 33% of animals, and facial neural crest-
specific knockout (KO) of the Prkar1a gene recapitulated Schwann
cell tumorigenesis [6].
Mouse models of NF1 and NF2 have also been generated by
creating the appropriate KO alleles. In contrast to the observations
in the Prkar1a+/− model, neither Nf1+/− nor Nf2+/− mice develop
Schwann cell tumors [7]. However, tissue-specific KO of these genes
does recapitulate neoplasia in Schwann cells and other tissues [8–11].
Because the genetics of NF have been well described, this informa-
tion has been used to study signaling pathways that may contribute
to Schwann cell tumorigenesis. Neurofibromin contains a GTPase-
activating protein (GAP) domain, which promotes the return of Ras
to its inactive guanosine 5c-diphosphate–bound state. When neuro-
fibromin is lost, Ras signaling is up-regulated, thereby causing activa-
tion of downstream effectors such as extracellular signal–regulated
kinase (ERK) and Akt [12–16]. In contrast, merlin is a member of
the ezrin-radixin-moesin family of proteins that links the cytoskeleton
to membrane signaling complexes. Although merlin does not have a
GAP motif, nor does it directly interact with Ras, it can interfere with
the complex of ezrin-radixin-moesin family proteins that couples Ras
signaling to cytoskeletal changes that occur during cell division [17].
As a result, alterations in ERK and Akt signaling may also occur
[17,18]. Loss of merlin can also cause activation of the small G pro-
teins Rac and Rho and their downstream effectors [19]. These path-
ways are also activated indirectly by loss of neurofibromin in tumors
through the downstream effectors of Ras signaling, including the PI3K
pathway [20].
In contrast to studies showing the effects of mutations in the NF
genes, activation of the PKA pathway does not have a well-
established role in Schwann cell tumorigenesis, despite the fact that
both humans and mice with PRKAR1A/Prkar1a mutations develop
these neoplasms. In this study, we sought to characterize, in detail,
the Schwann cell tumors arising in our tissue-specific KO model of
Prkar1a and to study the effects of this genetic manipulation on the
function of neurofibromin and merlin. We report that ablation of
Prkar1a in Schwann cells leads to posttranscriptional loss of both
the Nf1 and Nf2 gene products. Despite these observations, this
unique model of Schwann cell tumorigenesis occurs in the absence
of Ras (and therefore ERK or Akt) pathway activation. However, ex-
pression of the small G proteins Rac and Rho is increased in the tu-
mors, and Rac activity is significantly elevated. Collectively, these
data indicate that PKA dysregulation triggered by loss of Prkar1a
causes Schwann cell tumorigenesis through pathways that overlap,
but are distinct from, those that cause NF1 and NF2.
Materials and Methods
Mouse Experiments
All mice were maintained in a sterile environment under 12-hour
light/dark cycles. All animal experiments were carried out in accor-
dance with the highest standards of animal care under an Institu-
tional Animal Care and Use Committee–approved protocol. The
generation of Prkar1aloxP/loxP and TEC3 mice has been previously de-
scribed [6,21]. For this study, TEC3KO (TEC3;Prkar1aloxP/loxP) ani-
mals were monitored weekly for tumor onset, which was defined as
the age at which a tumor of 0.5-cm linear dimension (as measured by
calipers) was first detected. Mice with bilateral tumors were designated
as having tumor onset at the time the first tumor reached 0.5 cm.
Immunohistochemistry
Tissue samples were fixed overnight in 10% formalin, processed,
and embedded in paraffin. Immunohistochemistry was performed
on 8-μm sections after antigen retrieval (Vector Laboratories, Burlin-
game, CA) with the following antibodies: phospho-Akt, Akt, phospho-
ERK, ERK (Cell Signaling Technology, Danvers, MA). Antigens were
incubated with the appropriate secondary antibodies, and color was
developed by adding DAB chromagen reagent (Vector Laboratories)
to each section for 1 to 2 minutes before counterstaining with hema-
toxylin, dehydrating, and coverslipping. Samples were analyzed on a
microscope (Model BX50; Olympus, Center Valley, PA), and images
were captured using Spot Basic v4.1 software. LacZ staining of frozen
tissues was performed as described [22] and visualized as above.
Immunofluorescence
Freshly dissected tissue samples were frozen in Tissue Tek Optimal
Cutting Temperature Compound (Sakura Finetek USA, Inc., Torrence,
CA). Sections, 8 μm in sizes, were fixed using cold acetone and per-
meabilized in 0.1% sodium citrate with 0.1% Triton X-100 detergent
(Sigma, St. Louis, MO). The following primary antibodies were pre-
pared as per the manufacturers’ recommendations in 3% BSA in
PBS: neurofibromin (sc-67), merlin (sc-331; Santa Cruz Biotechnology,
Santa Cruz, CA), and Prkar1a (#610610; BD Biosciences, San Jose,
CA). Slides were incubated with primary antibodies at room tempera-
ture for 45 minutes, washed, and incubated with Alexa Fluor 488–
conjugated secondary antibodies (Invitrogen, Carlsbad, CA) for
25 minutes in the dark. Samples were then washed, mounted with
DAPI mounting medium (Vector Laboratories), and visualized using
an Axioskop 40 microscope and AxioVision software (Carl Zeiss,
Inc., Thornwood, NY).
Western Blot Analysis
Primary Schwann cells were isolated and maintained as previously
described [23]. Wild type cells were harvested for protein using
Mammalian Protein Extraction Reagent (M-PER) with protease in-
hibitors (Pierce Biotechnology, Rockford, IL). Primary tumor sam-
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ples were dissected from TEC3KO animals and homogenized in pro-
tein lysis buffer containing 20 mM HEPES buffer, 20 mM NaCl, 5
mM EDTA, 5 mM EGTA, 0.5% Triton X-100, 1 mM DTT, and
protease inhibitors. Samples were resolved by SDS-PAGE before
being transferred onto nitrocellulose membranes (Pall Corporation,
East Hills, NY). Antibodies were obtained from the following sources
and used according to the manufacturers’ recommendations: Nf1 and
Nf2 (Santa Cruz Biotechnology); actin (20-33; Sigma); phospho-
ERK (Thr202/Tyr204; #9101), ERK (#9102), phospho-Akt
(Ser473; #9271), and Akt (#9272; Cell Signaling Technology). Blots
were developed using Western Lightning Chemiluminescence re-
agents (PerkinElmer, Waltham, MA) exposed to Blue Lite Autorad
film (ISC BioExpress, Kaysville, UT), and images were captured
using the GeneLine imaging system (Spectronics Corporation, West-
bury, NY). Quantitation of blots was determined by first normalizing
all the samples to the actin loading control using Genetools imaging
software (Spectronics Corporation, Westbury, NY). Band intensities
of the tumor samples were expressed as percentages in comparison to
the control Schwann cells (set to 1.0 arbitrary units). Statistics were
calculated using 2-tailed t test to generate P values.
Real-time Polymerase Chain Reaction
Primary murine Schwann cells and tumor samples (n = 6) were
harvested, and mRNA was prepared as described [24]. Wild type
Schwann cells were collected from one litter of embryos (n = 6)
pooled together to comprise the control sample. cDNA was prepared
using the iScript cDNA Synthesis kit (BioRad, Hercules, CA) and
analyzed by quantitative real-time polymerase chain reaction (PCR)
using iQ SybrGreen Supermix (BioRad). Each sample was run in
triplicate, and the values for all six tumors were averaged and compared
with those of the wild type Schwann cells. The following primer sets
were used for this study: Nf1 (forward: CACGGTGACCCCAGC-
TAT, reverse: TCCCTGATTCCATTTCTTGTC); Nf2 (forward:
GGGATTTTTAGCCCAAGAGG, reverse: ATCCACTCCAAG-
CAGCAACT); Prkar1a (forward: AGATCGTGGTGCAAGGAGAG,
reverse: CGGTCCAACTTAACGCA CTT); and Gapdh (forward:
GCAAATTCAACGGCACAGTCAAG, reverse: GTTC ACACCCA-
TCACAAACATGG). Additional primers sets are included as supple-
mental information.
G Protein Activation Assays
Ras, Rac, and Rho activity assays were performed on 18 TEC3KO
tumors using wild type rat Schwann cells (n = 3) as the comparative
control. Tumors and Schwann cells were lysed in buffer containing
1% NP-40, 10% glycerol, 20 mM Tris (pH 8.0), 137 mM NaCl,
1 mM MgCl2, 0.5 mM EDTA, and 10 mM sodium pyrophosphate.
The lysis buffer also contained the following protease inhibitors:
1 μg/ml aprotinin, 1 μg/ml leupeptin, 100 μg/ml PMSF, 1 mM
sodium vanadate, and 5 mM sodium fluoride. For each sample,
0.5 mg (Ras and Rac) and 1 mg (Rho) of protein was kept for 1 hour
at 4°C, rocking, with agarose beads conjugated to the substrate for
the appropriate activated G proteins: Raf1-RBD (Ras), PAK1-PBD
(Rac), and Rhotekin-RBD (Rho; Upstate, Charlottesville, VA). After
incubation, all samples were washed three times with lysis buffer,
resuspended in Laemmli buffer, and run on 12% SDS-PAGE for
Western blot using the following primary antibodies: anti-Ras (clone
RAS10; #05-516), anti-Rac1 (clone 23A8; #05-389; Upstate), and
RhoA (26C4; sc-418; Santa Cruz Biotechnology). Separate Western
blots were performed to test for the total amount of each G protein,
using actin (Sigma) as a loading control.
Results
Characterization of TEC3;Prkar1aloxP/loxP (TEC3KO) Mice
The TEC3 line was developed to express cre under the control of
the enhancer-less Tyrosinase promoter, which enables transgene expres-
sion in a limited subset of facial neural crest derivatives [21]. This cre
line was crossed with mice carrying a conditional null allele of Prkar1a
[6] to generate tissue-specific KO mice (TEC3;Prkar1aloxP/loxP, hence-
forth called TEC3KO animals). These mice were born at expected
Mendelian frequencies (data not shown) but developed unilateral or
bilateral tumors on the face (Figure 1, A and B) within a few months.
Observation of a cohort of 35 animals revealed that the penetrance of
the tumor phenotype was approximately 50% by 18 weeks of age and
nearly 80% by 40 weeks (Figure 1C). Although most mice manifested
the phenotype early in life, tumors could develop as late as 1 year.
To identify the tissue of origin for the schwannomas, TEC3KO
and control mice were studied by magnetic resonance imaging at a
time before palpable tumor development (Figure W1). Coronal and
axial scanning revealed small masses on the side of the face and lateral
to the orbit in TEC3KO animals. Although they frequently caused
extrusion of the orbit when larger (data not shown), these studies
did not indicate an origin from the optic nerve. Based on these data
and careful anatomic observation, we determined that the tumors
originated from Schwann cells originating in the trigeminal ganglion
and supporting the fifth cranial nerve, also referred to as the trigem-
inal nerve. Because the TEC3 transgene was not initially reported to
be expressed in this location, we reanalyzed the expression of the cre
by crossing it to mice carrying the Rosa26lacZ reporter allele [25].
This analysis revealed robust expression of cre in Schwann cells of
the trigeminal ganglion (Figure W2), further supporting our observa-
tions that TEC3KO tumors arise from progeny of these cells.
Histopathology of TEC3KO Tumors
We have previously described the TEC3KO tumors as schwannomas,
although detailed histopathologic characterization was not per-
formed [6]. To better understand the biology of these lesions, they
were analyzed according to the recently published guidelines de-
scribed for the Genetically Engineered Mouse classification of PNSTs
[26]. TEC3KO tumors were very myxoid (Figures 1, A and B, and
W3), and consisted mainly of spindle cells with many mitotic figures
and elongated nuclei (Figure W3, A and B). There were areas of
marked cellularity and cellular atypia, and in some cases, inflamma-
tory cells were present. According to the diagnostic criteria for
PNSTs, the TEC3KO tumors were classified as Genetically Engi-
neered Mouse schwannoma, grades II and III [26]. This classification
signified that, similar to the schwannomas in CNC patients, these
tumors may behave as malignant schwannomas. Additionally, nearby
tissue was impacted such that the bones of the skull underwent re-
modeling to accommodate larger tumors. Although there was no ac-
tual invasion of the skull cavity and the mice showed no signs of
neurologic problems, the tumors would often obstruct the eye caus-
ing visual impairment. Interestingly, there have been no signs of me-
tastases with these schwannomas, even as they grew to nearly 1.5 cm
in diameter (data not shown).
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A previous report from our laboratory showed that cyclin D1 was
up-regulated in Prkar1a null mouse embryonic fibroblasts (MEFs)
[24]. In line with these data, TEC3KO tumors revealed heavy stain-
ing for this marker by immunohistochemistry, even in areas where
cell proliferation was not obvious (Figure W3C ). The heterogeneity
of these tumors was further observed by LacZ staining of frozen
tissue sections taken from TEC3KO animals carrying the Rosa26lacZ
allele [22]. Analysis of this staining revealed that both cre-positive
and cre-negative cells were present in the tumors, further confirming
their heterogeneity (Figure W3D).
Effects of Prkar1a Ablation on the NF Proteins in
TEC3KO Schwannomas
As described above, mutations in NF1 or NF2 cause human
schwannomas and tissue-specific KO of these genes in mice can also
cause tumorigenesis [8–11]. To determine the effects of Prkar1a KO
on the NF proteins, the expression pattern of each of these gene pro-
ducts was tested in TEC3KO schwannomas. Immunofluorescence
experiments confirmed the loss of Prkar1a within the tumors (Fig-
ure 2, top) and, interestingly, demonstrated loss of both Nf1 and
Nf2 proteins as well (Figure 2, middle and bottom). These data were
further confirmed by Western blot analysis of tumor lysates, which
revealed almost complete lack of both Nf1 and Nf2 when compared
with wild type murine Schwann cells (Figure 3A). Additionally, simi-
lar loss of Nf2 was observed in primary TEC3KO tumor cultures
(data not shown).
To determine whether Prkar1a ablation caused down-regulation of
the NF genes at the transcriptional level, we performed quantitative
real-time PCR on tumor samples (Figure 3B). As a control, primary
murine embryonic Schwann cells were obtained from the dorsal root
ganglia of e12.5 embryos [23]. Because these cells are slow growing
and have a short life span, all cells obtained from one litter of wild
type animals (n = 6) were pooled and used for analysis. As expected,
Prkar1a levels were significantly down-regulated in the tumors com-
pared with WT Schwann cells. Residual Prkar1a message is likely
detected due to the heterogeneity of the tumors and the presence
of non–Schwann cells (e.g., endothelial cells and immune cells). In-
triguingly, transcript levels for both Nf1 and Nf2 were elevated at
least 10-fold (corresponding to a ΔΔC t value of 3.32) in TEC3KO
schwannomas compared with wild type Schwann cells. To rule out
somatic mutation as a mechanism by which the protein can be
down-regulated in the presence of normal levels of mRNA, we se-
quenced the Nf2 cDNA from three independent TEC3KO tumors
and found no evidence of transcript alterations. These data suggest
that there may be posttranscriptional regulation of NF gene expres-
sion after Prkar1a mutation, although the mechanism of these altera-
tions is not yet known.
Signaling Pathways in TEC3KO Schwannomas
Previous work has shown that both neurofibromin and merlin can
inhibit proliferation by down-regulating Ras signaling and therefore
Figure 1. Tumor incidence and anatomic localization of tumors in TEC3KO mice. (A, B) A typical schwannoma is shown in a TEC3KO
mouse. Note the gelatinous consistency of the tumor and its localization to the facial nerve lateral to the orbit. (C) Kaplan-Meier plot of
tumor onset in a cohort of TEC3KO animals (n = 35). Animals were monitored for 40 weeks of life, and tumor onset was considered
when a tumor reached 0.5 cm in diameter.
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its downstream effectors, Akt and ERK [17,27,28]. To examine
the extent of activation of these pathways in the TEC3KO tumors,
we analyzed tumors for total and activated (phosphorylated) Akt
and ERK. Surprisingly, immunohistochemistry staining (Figure 4A)
revealed a complete lack of activation of either of these pathways, which
was confirmed by Western blot analysis of tumor lysates (Figure 4B).
Quantitative analysis of the Western blot data revealed that there were
significant decreases in total Akt (P < .0001), phospho-Akt (P = .0022),
and total ERK (P = .0072) in tumors. Phospho-ERK expression was
essentially unmeasurable in the tumors, making statistical analysis im-
practical. Furthermore, although the levels of Ras expression seemed to
be elevated in the TEC3KO tumors, the active (GTP-bound) form of
the protein was significantly decreased compared with levels in normal
rat Schwann cells (P = .0096; Figure 5, A and B).
Additional molecules thought to be important downstream effec-
tors of the NF proteins include the small G proteins Rac, Cdc42, and
Rho. Although neurofibromin may affect these signaling molecules
as downstream targets from Ras, merlin has been shown to play a
direct role in the inhibition of Rac/Cdc42, Rho, and PAK1 signaling
[17,29–31]. In TEC3KO tumors, not only the expression of Rac1 (P =
.0439) but also its activity (P = .0098) was significantly increased com-
pared with normal rat Schwann cells (Figure 5, A and B). Rho expres-
sion was increased overall in the tumors (P = .0092); however, its
activation was highly variable, failing to produce a significant differ-
ence between levels of Rho-GTP in normal Schwann cells compared
with the panel of 18 tumors taken as a whole (P = .1789; Figure 5, A
and B; and data not shown). Cdc42, which is highly homologous to
Rac1, was observed in wild type Schwann cells and was essentially un-
changed in the tumors (data not shown). Finally, real-time PCR was
performed to check the transcript levels of each G protein (Ras, Rac1,
and RhoA); similarly to the protein expression, mRNA expression was
elevated for each gene (Figure W4).
Discussion
As in many biochemical processes, the study of inherited syndromes
has contributed substantially to our knowledge of functional interac-
tions. For Schwann cell tumorigenesis, the major syndromes that are
involved are NF1, NF2, schwannomatosis, and the CNC, all multiple
neoplasia syndromes associated with Schwann cell tumors.
At the biochemical level, it was previously reported that there are
interactions between PKA and the NF proteins, as PKA is known to
phosphorylate neurofibromin, although the functional effects of this
reversible modification are unclear [32,33]. Additionally, loss of neu-
rofibromin has been shown to up-regulate cAMP levels, which would
presumably increase PKA activity [34]. PKA has also been shown to
phosphorylate merlin at Serine-518, the same site that is phosphory-
lated by the p21-activated kinase [35]. At the functional level, this
phosphorylation reduces the ability of merlin to suppress cell growth,
potentially through heterodimerization with ezrin. Moreover, merlin
has been shown to function as an A-kinase anchoring protein by
binding directly to the Prkar1b subunit, although no binding of
Prkar1a was observed [36].
Figure 2. Decreased expression of the NF proteins in TEC3KO
schwannomas. Frozen tissue sections from the same tumor were
stained by immunofluorescence for Prkar1a, neurofibromin, and
merlin proteins. Tumor stroma (S) stained positively and was
therefore used as a control for staining. The dashed line marks
the interface between stromal and tumor tissues. As expected,
Prkar1a was not present in the tumor tissue (T), but surprisingly
both neurofibromin and merlin were absent as well.
Figure 3. Down-regulation of Nf1 and Nf2 occurs at the posttran-
scriptional level. (A) Protein lysates of WT Schwann cells and six
different TEC3KO schwannomas were analyzed for Nf1 and Nf2 pro-
teins. Note the marked down-regulation of both proteins in compari-
son to the actin control. (B) Real-time PCR analysis of mRNA for
Prkar1a, Nf1, and Nf2 from WT Schwann cells and TEC3KO tumors.
Results are shown as averaged expression among all six tumors
compared with WT Schwann cells. ΔΔCt was calculated compared
with a Gadph standard, and error bars represent the relative SD.
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In TEC3KO schwannomas, the most striking observation was the
marked down-regulation of both neurofibromin and merlin in the
tumors, shown both by immunofluorescence (Figure 2) and by West-
ern blot analysis (Figure 3A). Furthermore, this alteration occurs at
the posttranscriptional level, because mRNA levels of both genes
were significantly elevated when compared with normal Schwann
cells (Figure 3B). Moreover, at least in the case of Nf2, there were
no somatic mutations found in the gene that would account for its
down-regulation. These findings suggest that PKA may play a role in
regulating the stability of the NF proteins. Such a role for PKA has
previously been described, because phosphorylation by PKA has been
shown to promote the degradation of proteins such as GRIP1 and
Matrin 3 by triggering ubiquitin-dependent proteolysis [37,38].
The converse can also occur, because PKA causes cellular redistribu-
tion of RhoA and, through phosphorylation, reduces its degradation
rate [39]. We have observed the same phenomenon in Prkar1a KO
MEFs, in which an enhanced stability of the cell cycle progression
marker cyclin D1 was observed [24]. These observations are all con-
sistent with the recently proposed role of Prkar1a in modulating
autophagy and the mTOR pathway [40]. Further studies are required
to elucidate the role of autophagy or proteasomal-mediated degrada-
tion in the present observations.
From prior studies of the function of the NF genes, it has been
proposed that there are three major downstream pathways that con-
tribute to the Schwann cell tumorigenesis phenotype. Ablation of
neurofibromin causes activation of the Ras, ERK, and Akt pathways,
whereas loss of merlin causes increases in small G protein (Rac/
Cdc42/Rho) signaling [19,41]. This latter pathway is also activated
by mutations in Nf1, because Rac and Rho may be activated by path-
ways downstream of Ras [42,43].
Because we observed striking down-regulation of both neuro-
fibromin and merlin in the TEC3KO model, we expected to find in-
creases in the activation of each of the three pathways (ERK, Akt,
and small G proteins). Surprisingly, Ras activity was significantly de-
creased in TEC3KO tumors compared with wild type Schwann cells,
and furthermore, there was a significant decrease in the activation
of both Akt and ERK in the tumors. These results mimic earlier
findings from our laboratory in Prkar1a KO MEFs, which also
showed that immortalization occurred independently of ERK or
Akt activation [24]. Interestingly, previous studies on neurofibromin
have indicated that Akt signaling, particularly through mTOR, is
most important for tumor growth [12,13], whereas loss of merlin
seems to up-regulate signaling primarily through ERK [17]. Data
from the TEC3KO model indicate that there may be an alternative
pathway, mediated by PKA activation, that can effectively promote
Schwann cell hyperplasia as well. In addition, we observed a marked
up-regulation of Rac activity, whereas Rho was not consistently ac-
tivated. Rac and Rho are small G proteins of the Rho family, and
although they have different functions, they are both shown to be
important for normal Schwann cell function. Rac seems to be in-
volved in membrane ruffling and establishment of Schwann cell–
neuron interactions during myelin formation [41,44]. Conversely,
Figure 4. Loss of Akt and ERK pathway activation in TEC3KO schwannomas. (A) Paraffin-embedded sections of TEC3KO tumors were probed
for the phosphorylated (activated) and unphosphorylated (total) forms of Akt and ERK. Stromal tissue stained positively for each protein and
was therefore used as a control for staining. (B) Western blot analysis of the same lysates as in Figure 3A for p-Akt, Akt, p-ERK, and ERK.
Actin is shown as a loading control. Note that ERK was probed from the same blot as in Figure 3A, and thus, the actin control lanes are the
same. Quantitation of band intensities was performed, and tumor samples were compared with Schwann cells. Values shown below the
blots represent the relative band intensity compared with the Schwann cell sample (set to 1.0) after normalization to actin.
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Rho, which is activated by integrin signaling, is required for stress
fiber formation and cell motility [45]. Nonetheless, despite their dif-
ferences in function, both proteins are known to be dysregulated in
Schwann cell neoplasias [19].
There is good evidence that PKA can specifically affect the activ-
ity of Rac and Rho, although clearly those effects are cell type– and
condition-specific [46]. The interaction between PKA and Rho is
better defined, such that PKA directly phosphorylates Rho at S188
and negatively regulates its activity [47]. The mechanism of this
regulation entails PKA phosphorylation leading to enhanced binding
of Rho to the cytosolic Rho GTP-dissociation inhibitor (Rho-GDI)
protein, which sequesters Rho from its active location at the cell
membrane. However, relocation from the membrane is not solely
associated with enhanced GTPase activity. It seems that PKA phos-
phorylation can also cause dissociation between the total GTP-loaded
form of Rho and its intracellular activity [47–49].
Unlike Rho, Rac lacks a direct PKA phosphorylation site, although
enhanced PKA activity increases GTP-loaded Rac and seems to also
enhance its activity. The mechanism by which this occurs has yet to
be elucidated, but it has been proposed that alterations in Rac-GTP
exchange factors may be involved [50].
For both Rho and Rac, PKA activation has generally been associ-
ated with alterations in protein activity without changes in protein
level. The exception to this is the decreased degradation of Rho,
where GDI binding S188 phospho-Rho enhances its stability. Thus,
although we observe significantly increased expression levels of both
Rho and Rac in our tumors, the effect on signaling through these
pathways is not so straightforward now.
In summary, studies to date of pathways leading to schwannoma
and PNST formation have revolved around Nf1 and Nf2 signaling
through Ras, PI3K, Akt, and ERK, as well as the downstream ef-
fectors Rac, Cdc42, and Rho. Although PKA is known to be im-
portant for Schwann cell growth, its role in this process has not
yet been elucidated. In this article, we present data indicating that
PKA may have multiple roles in promoting Schwann cell tumori-
genesis. First, it seems to modulate the stability of the NF proteins,
such that dysregulation of PKA leads to posttranscriptional loss of
these proteins during tumorigenesis. Secondly, PKA seems to signal,
either directly or indirectly, to the same downstream effectors acti-
vated by mutations in the NF genes. However, unlike activation of
Schwann cell tumorigenesis by NF mutations, PKA seems to pro-
mote tumorigenesis by a mechanism that excludes activation of
Ras, ERK, and Akt. Thus, PKA promotes Schwann cell tumors by
mechanisms that overlap but are distinct from those seen in NF-
associated tumorigenesis.
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Figure 5. Signaling analysis in TEC3KO tumors. (A) Representative blots from small G protein activity assays performed on 18 TEC3KO
tumors. Samples were probed for the proteins indicated at left, and actin was used as a loading control. (B) Quantification of results
from panel (A). Note the up-regulation of total forms of each protein; however, significant increases in activity levels were seen only with
Rac1. *P < .05, **P < .01.
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Supplemental Methods
Magnetic Resonance Imaging
Prkar1aloxP/loxP and TEC3KO mice were imaged under avertin
anesthesia by a 4.7-T Bruker MRI system using 120-cm ID, a
400-mT/M gradient insert, a 72-cm ID volume RF transmit, and
a 5-cm diameter surface receiver coil. Sequences were captured with
the T2-weighted, 137 × 137 × 1000 μm resolution, RARE sequence
at 2579-ms repetition time and 47.4-ms effective echo time, and
then averaged four times. Scans were 5 minutes 30 seconds long, with
a 256 × 256–matrix size, 3.5-cm field of view, and 1-mm slice thick-
ness. Both coronal and axial views were obtained for each mouse.
LacZ Enzymatic Stain
LacZ staining of frozen tissues was performed as described (Yin
et al., 2008). Images were visualized on an Olympus BX50 micro-
scope and captured using Spot Basic v4.1 software.
Figure W1. MRI analysis of TEC3KO tumors. Mice were subjected
to monthly MRI scans starting at 1 month of age and continuing
for 5 months. Images shown are from 4-month-old mice. Note the
presence of small tumor growth in the TEC3KO mouse (arrows).
Primers
The following primers were used for real-time PCR amplification:
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46, 37–42.






Figure W2. Cre expression in TEC3KO embryos. (A–D) Histologic
sections of lacZ-stained WT (A and C) or TEC3KO (B and D) em-
bryos are shown at low (A and B) and high (C and D) power. Note
the localization of staining to the trigeminal ganglion (Tg). (E)
Whole-mount embryo staining of TEC3KO animals localizes cre
activity to the lateral aspect of the face. BA1 indicates branchial
arch 1; E , eye; FNP, frontonasal process; HB, hind-brain; SCG, su-
perior cervical ganglion.
Figure W3. TEC3KO schwannomas exhibit enhanced staining for
cyclin D1 but show heterogeneous cre activity. (A and B) Hematox-
ylin and eosin staining of a TEC3KO tumor, showing schwannoma
characteristics and heterogeneity. (B) Example of mitotic figures
within the tumor (arrows). (C) Immunohistochemistry for cyclin D1
(Santa Cruz Biotechnology, Santa Cruz, CA) from a typical TEC3KO
schwannoma shows high-level staining inmost cells, although areas
with low staining are also noted. (D) LacZ enzymatic staining of fro-
zen tumor sections reveals heterogeneous activity of cre, with both
cre-positive (blue) and cre-negative (nonblue) cells present in the tis-
sue. Nuclei are visualized with nuclear fast red.
Figure W4. Small G proteins are up-regulated at the mRNA level
in TEC3KO tumors. Real-time PCR analysis of mRNA for the indi-
cated small G proteins was performed for WT Schwann cells and
TEC3KO tumors. Results are shown as tumor expression com-
pared to WT Schwann cells, and ΔΔCt was calculated compared
to a Gadph standard.
